Drugs / VXA-RSV-f
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02830932 | Jun → Sep 2016 | respiratory syncytial virus infectious disease | Vaxart | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VXA-RSV-f | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02830932 ↗ |
| Modality | Vaccine | “Adenoviral-Vector Based Respiratory Syncytial Virus (RSV) F Protein Vaccine” NCT02830932 ↗ |
| Route | Oral | “Administered Orally” NCT02830932 ↗ |